about
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gainPreliminary and ongoing French multicenter prospective naturalistic study of adverse events of antipsychotic treatment in naive children and adolescents.The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk.Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management.Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approachAntipsychotic drugs and obesity.Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.Risperidone induced weight gain leading to benign intracranial hypertensionGender and race disparities in weight gain among offenders prescribed antidepressant and antipsychotic medicationsEffectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders: results from a 12-month, real-world study.Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications.Antipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndromeImproving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods.Physical activity level and medial temporal health in youth at ultra high-risk for psychosisThe Obesity-Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients.Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.Obesity and psychotropics.Safety of olanzapine use in adolescents.Do antipsychotics increase diabetes risk in children and adolescents?Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management.Running for your life: A review of physical activity and cardiovascular disease risk reduction in individuals with schizophrenia.Diabetes and Schizophrenia.Weight gain with add-on second-generation antipsychotics in bipolar disorder: a naturalistic study.Once-monthly paliperidone palmitate in early stage schizophrenia - a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia.Superwellness Program: a cognitive-behavioral therapy-based group intervention to reduce weight gain in patients treated with antipsychotic drugs.Decreased 5-HT2cR and GHSR1a interaction in antipsychotic drug-induced obesity.Enhancing metabolic monitoring for children and adolescents using second-generation antipsychotics.Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study
P2860
Q28266158-09D98553-4857-4BA4-88F5-F0A8ED8CFF2BQ33835596-D315B750-0F08-432F-A00C-3640F55FD657Q33849136-33E5E2CA-BAFD-4B1A-BAF0-5D0E7061B9DEQ33878816-7FAA6533-2B0C-486E-B04F-78933DD075BEQ34292768-40659682-25D3-4DC8-ACAA-EEACBEDB8DB8Q34464293-400DDB2E-6198-4306-9317-B6A06F21CE62Q34648940-8AA90B0B-968B-4D9B-A0FE-5953D560B43DQ35016170-496E61C7-126A-4BDB-99FB-218A3D1515C8Q35145284-5B6C554B-0F48-4F81-AA4B-B3CE22C2E90CQ36060797-9B42B716-3DE2-4347-B609-B4E7CEA9106DQ36075717-A9C2F2D5-CDFE-4BDD-9CA6-1297C30174F3Q36966228-33689AE9-A7DC-4230-BC6D-81C64CE86EEBQ37043479-D9777A6C-569C-4F46-8331-29A6DE074B65Q37354917-225DAE92-5E0D-425D-8C1F-78E66427BDB3Q37479158-32239852-0705-4B3F-A917-7CAF3F790B5BQ37637480-6E07D95D-0789-46F5-8051-9ED23DE660FEQ37684797-B21F29F5-8705-4BA9-B572-E8726D1917D6Q37947095-B1075A95-58DA-4D0B-A6FB-3ACB7D15DE92Q37954390-B2D42F49-1D20-408E-AB0A-A23CC10FBB9AQ38123236-BB5DB9EC-1EC0-4306-A98B-FD1C9B6A787AQ38283956-29405380-2968-4162-801E-C608917F758CQ38504254-9B67C8D3-8E11-4454-936A-A2DF788CE095Q38656912-32AC99F4-EF35-4278-A6A7-5FF10AB29EB7Q38709352-87DA8290-EC3A-4FE6-BBF8-1ABB7159ECBEQ38838191-43EC43BA-C006-4736-8D9A-CA8380910D16Q41634413-A78349A4-441E-44FA-BB37-38A2D1C0705DQ47228167-7D22511E-CEAE-46A7-B26D-725493FD1E46Q48336234-767D8ED0-047D-4E06-815A-DB9233A6CA3DQ50072523-FBD52FCC-581E-49AA-8557-BF6C0E871BBBQ57164581-7DF838B6-6EEF-4ECB-801A-D71AC9EC7C61
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Management of antipsychotic-related weight gain
@ast
Management of antipsychotic-related weight gain
@en
Management of antipsychotic-related weight gain
@nl
type
label
Management of antipsychotic-related weight gain
@ast
Management of antipsychotic-related weight gain
@en
Management of antipsychotic-related weight gain
@nl
prefLabel
Management of antipsychotic-related weight gain
@ast
Management of antipsychotic-related weight gain
@en
Management of antipsychotic-related weight gain
@nl
P2860
P3181
P356
P1476
Management of antipsychotic-related weight gain
@en
P2093
Christoph U Correll
Lawrence Maayan
P2860
P304
P3181
P356
10.1586/ERN.10.85
P407
P577
2010-07-01T00:00:00Z